Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Evolv expands partnership with Gillette Stadium and becomes official provider for fan security screening

Evolv has renewed and expanded its partnership with Gillette Stadium, which began in 2021, so that KI-supported Evolv Express security lanes will be installed at additional entrances. The systems are designed to detect concealed weapons at normal walking speed and have already screened more than seven million visitors at the stadium. The contract extension strengthens Evolv’s presence in the greater Boston area; the company reports 36.6% revenue growth last year, Q2 revenue of $32.5 million (+29%) and remains unprofitable despite strong demand (negative EBITDA). Analyst reactions raised price targets and ratings but highlighted the still-present valuation premium. » More on de.investing.com
Evolv Technologies reaches new 52-week high at $7.45

Shares of Evolv Technologies Holdings Inc. rose to a new 52-week high of $7.45 after the stock gained about 143.77% over the past year. The company reported revenue growth of 36.71%, a positive EBITDA in the first quarter, a $75 million credit facility from MidCap Financial and a $19.36 million school contract with Gwinnett Schools; analyst price targets range from $5.50 to $8.25. Positive analyst revisions (Northland, Craig-Hallum, Lake Street) and the resolution of an FTC probe are cited as drivers of the optimistic sentiment. » More on de.investing.com
Evolv Technologies reaches new 52-week high after strong growth and positive analyst ratings

Evolv Technologies' stock climbed to a 52-week high of $7.10, supported by revenue growth of 36.71% and strong performance over the past year. The company also secured a $75 million credit facility to strengthen its subscription-based business and significantly exceeded revenue expectations in the first quarter. Analysts upgraded the stock to 'Outperform' or 'Buy' due to improved financial metrics and strategic initiatives. » More on de.investing.com

Financials

In the last quarter, EVOLVA N had revenue of €0 and net profit of -€688.15K

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-688.15K	-
EBITDA	-839.6K	-

Fundamentals

Metric	Value
Market capitalization	€17.38M
Number of shares	7.21M
52-week high/low	€22.44 - €0.67
Dividends	No
Beta	-0.05
P/E ratio	-17.67
PEG ratio	0.59
P/B ratio	3.08
P/S ratio	0.00

Company profile

Evolva Holding SA discovers, researches, develops, and commercializes nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. It offers various ingredients comprising Veri-te Resveratrol, a nature-made polyphenol that occurs naturally in grapes and other plants, including peanuts, cranberries, and berries; L-Arabinose, a flavoring agent used in Maillard reaction; Valencene, an aroma component of citrus fruit and citrus-derived odorants; Nootkatone, an aroma ingredient of grapefruit obtained via biochemical oxidation of valencene; and Vanillin, a primary component of vanilla bean extract. The company was founded in 2004 and is headquartered in Reinach, Switzerland.